Quarterly ResultAug 6, 2026, 06:17 AM
Haemonetics Q1 Revenue +5.6% to $339.4M; Diluted EPS $0.72
AI Summary
Haemonetics reported first-quarter net revenues of $339.4 million, a 5.6% increase year-over-year, with diluted earnings per share rising to $0.72. Net income for the quarter was $33.0 million, a slight decrease from the prior year. The company also announced a segment reorganization, combining Plasma and Blood Center into Apheresis and renaming Hospital to MedSurg, effective June 5, 2026.
Key Highlights
- Net revenues increased 5.6% to $339.4 million.
- Net income was $33.0 million, down 3.0% year-over-year.
- Diluted EPS rose 2.9% to $0.72.
- Operating income grew to $57.5 million from $53.9 million.
- Cash and cash equivalents totaled $223.4 million.
- Segment reorganization: Plasma & Blood Center combined into Apheresis.
- Hospital segment renamed MedSurg, effective June 5, 2026.
- $325.0 million remains for share repurchases under the 2025 program.
Price Impact
More from HAE